Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 Substudy 04A of MK2140 in PD-1/L1-refractory urothelial carcinoma
NL-OMON51831Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zilovertamab vedotin in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Merck & Co. Primary endpoints: Adverse events, Study intervention discontinuations due to adverse events and 1 more. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON51831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51831.